TG Therapeutics (TGTX) Set to Report Quarterly Earnings
Nov 2, 2024
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Analysts Favor a 'Buy' Recommendation
Pliant Therapeutics, Inc. (NASDAQ:PLRX) has recently received a consensus recommendation of "Buy" from analysts that have been monitoring the stock. This consensus is based on the evaluations of nine Wall Street firms that have issued ratings on Pliant over the last year.
Current Stock Price
The current trading price of Pliant Therapeutics is $14.52, which reflects an increase of 3.20% (+0.45) as of November 1, 2024.
Consensus Ratings Explained
MarketBeat compiles analyst recommendations using their latest ratings from Wall Street experts. Each rating is assigned a score ranging from 1 (sell) to 4 (strong buy). Ratings are averaged to derive a consensus score that classifies the stock into categories such as sell, hold, buy, or strong buy. For Pliant Therapeutics, the consensus rating indicates a general approval among analysts.
Breakdown of Ratings
Out of the nine analysts covering Pliant Therapeutics, eight have given the stock a "buy" recommendation, while one has rated it as a strong buy. This suggests a strong belief in the stock's potential.
Price Target Expectations
The average twelve-month price target set by these analysts stands at $40.57. The highest individual price target projected for PLRX is $45.00, whereas the lowest target is $33.00. This average target suggests a significant potential upside of approximately 179.42% compared to its current price.
Analyst Activity Over Time
The analysts' evaluations of Pliant Therapeutics may change over time, reflecting their ongoing analysis of the company’s performance and market conditions. Continuous monitoring of these ratings can provide investors with insights into how expert analysts perceive the company's growth potential.
Comparative Analysis
| Type | Pliant Therapeutics | Medical Companies | S&P 500 |
|---|---|---|---|
| Consensus Rating Score | 3.11 | 2.79 | 2.50 |
| Consensus Rating | Buy | Moderate Buy | Hold |
| Predicted Upside | 179.42% Upside | 15,871.88% Upside | 10.59% Upside |
| News Sentiment Rating | Neutral News | Neutral News | Positive News |
Recent Analyst Ratings
| Date | Brokerage | Analyst Name | Action | Rating | Price Target | Upside/Downside | Details |
|---|---|---|---|---|---|---|---|
| 9/13/2024 | HC Wainwright | Reiterated | Buy | $38.00 | +220.95% | ||
| 9/9/2024 | Leerink Partners | F. Khurshid | Upgrade | Strong-Buy | |||
| 8/8/2024 | Cantor Fitzgerald | Reiterated | Overweight | ||||
| 5/7/2024 | Citigroup | Lower Target | Buy | $44.00 | +223.53% | ||
| 12/13/2022 | Stifel Nicolaus | Initiated Coverage | Buy | $33.00 | +73.23% |
Overall, Pliant Therapeutics appears to be a favorable investment opportunity as indicated by the positive ratings from analysts and the strong price target expectations.
Pliant, Therapeutics, Analysts